Profiling canine mammary tumors: A potential model for studying human breast cancer

Gherman, Luciana-Madalina; Chiroi, Paul; Nuţu, Andreea; Bica, Cecilia; Berindan-Neagoe, Ioana

doi:10.1016/j.tvjl.2023.106055

The Veterinary Journal

2024

DOI: 10.1016/j.tvjl.2023.106055

|View full text |Cite

Profiling canine mammary tumors: A potential model for studying human breast cancer

Luciana-Madalina Gherman,

Paul Chiroi,

Andreea Nuţu

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite1

Independent1

Authors

Journals

Cited by 2 publications

References 152 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Molecular Markers in Canine Mammary Tumors

Gherman,

Isachesku,

Zanoaga

et al. 2024

Acta Veterinaria

Self Cite

View full text Add to dashboard Cite

Canine mammary tumors (CMTs) are one of the most common neoplasms in female dogs. Unfortunately, the current diagnosis often occurs in later stages, and there is a pressing need for more comprehensive data on treatment options to improve overall prognosis. Consequently, the early detection of these tumors is critical for improving treatment outcomes and survival rates. As such, biomarkers are essential for improving the diagnosis, treatment, and prognosis of CMT, the reason for which further research is required to enhance our understanding of the disease. The most studied biomarkers for CMT are evaluated from serum and tissue samples using different molecular approaches and relate to proliferation and cell cycle. Several biomarkers were also described regarding cell damage, autophagy and apoptotic-related pathways, hypoxia, angiogenesis, EMT, invasion, metastasis or cancer stem features. Overall, biomarkers have shown the potential to be used as a tool for the early detection of mammary tumors in dogs. However, more research is needed to validate these biomarkers and to develop sensitive and specific diagnostic tests. In this regard, we aimed to review known biomarkers and their role in CMT comprehensively. We also encouraged further investigations of reliable biomarkers that could improve treatment outcomes and survival rates for dogs with this disease.

show abstract

Molecular Markers in Canine Mammary Tumors

Gherman,

Isachesku,

Zanoaga

et al. 2024

Acta Veterinaria

Self Cite

View full text Add to dashboard Cite

show abstract

LncRNA Expression Profiles in C6 Ceramide Treatment Reveal lnc_025370 as a Promoter in Canine Mammary Carcinoma CHMp Cells Progression

Diao,

Zhao,

et al. 2024

CIMB

View full text Add to dashboard Cite

Canine mammary carcinomas (CMCs) represent the most prevalent form of cancer in female dogs, characterized by a high incidence and mortality rate. C6 ceramide is recognized for its multifaceted anti-cancer properties, yet its specific influence on CMCs remains to be elucidated. Long noncoding RNAs (lncRNAs), now recognized as functional “dark matter” in precision oncology, are particularly intriguing, with 44% of canine lncRNAs exhibiting tissue-specific expression. In this study, we performed a thorough analysis of lncRNA expression profiles to uncover the mechanisms behind C6 ceramide’s anti-cancer activity in CHMp cells. Our findings reveal that C6 ceramide notably inhibits the proliferation of CHMp cells. RNA sequencing identified 4522 lncRNAs with expression changes following C6 ceramide treatment, of which 2936 were upregulated and 1586 were downregulated. Further investigation into Lnc_025370 showed that it is predominantly nuclear-localized and is significantly downregulated by C6 ceramide treatment. Functional studies discovered that overexpression of Lnc_025370 enhances the growth and metastatic capabilities of CHMp cells, which is associated with an increase in NRG1, and concurrently diminishes the anti-cancer effectiveness of C6 ceramide in vitro. Mouse xenograft models also showed that Lnc_025370 overexpression promotes tumor growth and Ki67 expression. Together, our results suggest that Lnc_025370 acts as a pivotal target mediator of C6 ceramide’s anti-cancer effects, facilitating the malignant progression of CHMp cells.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Profiling canine mammary tumors: A potential model for studying human breast cancer

Cited by 2 publications

References 152 publications

Molecular Markers in Canine Mammary Tumors

Molecular Markers in Canine Mammary Tumors

LncRNA Expression Profiles in C6 Ceramide Treatment Reveal lnc_025370 as a Promoter in Canine Mammary Carcinoma CHMp Cells Progression

Contact Info

Product

Resources

About